Industrial biotech marketing: it’s complicated
Industrial biotech startups often need to communicate with investors, buyers, technical teams and commercial decision makers at the same time.
This article explores why that messaging is especially complex, and how a clear narrative, executed through a focused marketing plan- can help companies balance platform potential, buyer relevance and near-term commercial priorities.
Industrial biotech founders and leadership teams often face a significant challenge when the one-to-one conversations need to turn into consistent narratives and coherent messaging.
For industrial biotech startups and scale-ups, understanding what to communicate, to whom, and at which stage of growth is rarely straightforward. Figuring out how to create a top line narrative that stays consistent and relevant with all their (very different) target audiences is an even harder challenge.
Unlike many other sectors, industrial biotech companies often need to balance multiple, different, equally relevant stakeholders simultaneously.
It is not unusual for an industrial biotech company to entertain conversations with investors (VCs or CVCs) and, one the buyer side, technical users, P&L owners and decision-makers, often across multiple different application industries, all at once.
In practice, founders are usually very capable of adapting their messaging when sitting face-to-face with a potential customer, investor, or partner. A technical founder speaking with an R&D team will naturally frame the technology differently than during a fundraising discussion with a venture capital fund or a meeting with a procurement stakeholder.
That adaptability is not the problem.
The complexity emerges when startups begin scaling their visibility and commercial activities beyond individual conversations.
As companies start building longer sales pipelines, entering multiple application markets, or increasing investor outreach, they inevitably need a more coherent outward-facing narrative across the communication channels that stakeholders will check independently over time. In industrial B2B environments, those channels are often relatively limited but highly influential: company websites, LinkedIn activity, technical and industry press coverage (conversely influencing AI searches), investor materials, conference presentations, and sales materials.
The challenge is that all of these touchpoints need to tell a story that feels coherent while still resonating with audiences that evaluate the business through very different priorities.
Narratives and Marketing in industrial biotech: a three-layer cake
The communication complexity in industrial biotech is rarely caused by a single issue. More often, it is the result of several layers overlapping simultaneously.
First layer: investor narratives and buyer narratives are not identical
One of the first communication tensions industrial biotech startups encounter is the need to balance narratives that resonate with investors and narratives that resonate with buyers.
These narratives are not completely divergent, but they are rarely identical either.
Investors are often interested in understanding the long-term potential of the technology. They may focus on platform scalability, defensibility, intellectual property, future market expansion opportunities, techno-economic advantages, or manufacturing scalability over time.
Buyers, however, are usually evaluating a much more immediate question:
How does this solution help solve a concrete problem inside my business today?
As a result, buyer-facing communication tends to be much more operational and application-specific. Buyers are often evaluating formulation compatibility, manufacturing integration, production reliability, implementation feasibility, regulatory considerations, or commercial competitiveness within their own category.
This means industrial biotech startups frequently find themselves balancing two realities simultaneously:
communicating long-term technological value and future scale potential,
while also demonstrating immediate practical relevance within a specific industrial context.
The nuance matters because a message that feels compelling in an investor pitch is not always the message that creates confidence with industrial buyers.
Second layer: convincing multiple application industries and multiple stakeholders within a single buyer
One of the most important communication realities in industrial biotech is that buyers are rarely searching for industrial biotech solutions in abstract terms.
They are searching for solutions to operational, formulation, manufacturing, sourcing, or performance problems, where industrial biotech happens to be the enabling technology.
This distinction is important.
A company may internally define itself as an industrial biotech platform business, but a personal care manufacturer, food producer, textile company, or materials player is usually evaluating the company through the lens of a specific commercial or technical challenge.
The complexity increases further because many industrial biotech startups operate across several application industries simultaneously.
A company may have relevance across food, personal care, home care, textiles, agriculture, biomaterials, or specialty chemicals. While the underlying technology platform may remain the same, the pain points, priorities, language, and expectations within each application industry can differ significantly.
A personal care company may prioritise performance claims, formulation compatibility, and consumer positioning. A food company may focus more heavily on scalability, palatability, and wether a solution supports clean label claims. CDMOs might be focused on what process bottlenecks the technology is removing.
Even within a single organisation, the sales teams of startups and scaleups might need to convince different people and teams, with different agendas.
Formulation teams, procurement stakeholders, marketing, and commercial leadership often evaluate the same technology through different lenses. The people assessing technical feasibility are not always the same people evaluating commercial viability, long-term business implications or- very importantly-signing off on an investment.
As a result, industrial biotech companies often need narratives that can resonate across several layers of technical and commercial decision-making at the same time.
Third layer: remaining visible and top of mind through long sales cycles
The third layer of complexity is not unique to industrial biotech, but it becomes particularly relevant in sectors with long industrial sales cycles.
Industrial biotech sales cycles are rarely (or, to be more accurate, close to never) short.
From the first exploratory meeting to a joint development agreement, pilot, or commercial offtake agreement, timelines can easily extend across 12 to 24 months, sometimes longer.
During that period, several things typically happen.
Internal priorities within the buyer organisation may evolve. Different stakeholders may become involved in the evaluation process. Teams change. Budgets shift. The company may be discussed internally by people who have never directly met the startup team.
This means the external narrative of the company needs to remain coherent even when the founders themselves are not physically present in the room.
Stakeholders will independently check the company website, LinkedIn presence, technical materials, conference visibility, and industry press coverage to form impressions about credibility, maturity, relevance, and commercial fit.
Importantly, these touchpoints need to resonate not only with technical users but also with commercial decision makers and P&L owners, many of whom may not have deeply technical backgrounds.
Technical teams may care about validation data, formulation performance, or manufacturing capabilities. Commercial stakeholders are often more influenced by messages linked to competitiveness, supply stability, market differentiation, operational resilience, or commercial opportunity.
Strong industrial biotech communication therefore needs to function across both technical and commercial layers simultaneously.
How should industrial biotech startups approach this complexity?
The good news is that industrial biotech companies do not necessarily need completely different narratives for every stakeholder group.
What they need is a clear narrative hierarchy.
One of the most useful starting points is a very rigorous customer-centric exercise centred around two pillars.
The first is a deep understanding of target audiences and ideal customer profiles, including investors. This means understanding:
who the stakeholders are,
what problems they are trying to solve,
which risks they are evaluating,
what motivates adoption,
and who ultimately influences decision-making.
The second pillar is understanding which commercial or fundraising milestones matter most within the next 6, 12, or 18 months.
This is particularly important because startup narratives are not static exercises built for the next decade. In practice, messaging often needs to support relatively immediate strategic priorities.
That may require companies to make deliberate choices around message hierarchy and narrative emphasis.
A practical example
Imagine an industrial biotech startup with applications across personal care, textiles, and mineral processing.
From a long-term perspective, all three markets may represent meaningful commercial opportunities.
However, the company’s immediate strategic priority may be demonstrating traction in personal care because success in that market is expected to unlock the next fundraising round through off-take agreements or commercial partnerships.
In that scenario, the narrative should not necessarily give equal visibility and strategic weight to all three application industries at all times.
That does not mean the broader platform potential disappears. Investors may still care deeply about the future scalability of the technology across several sectors.
However, the communication hierarchy should reflect the company’s immediate commercial reality and near-term milestones.
In practice, this is where many startups struggle.
There is often pressure to communicate every possible market opportunity simultaneously in order to demonstrate platform breadth and long-term scale potential. However, when everything is prioritised equally, the narrative can quickly become diffuse and difficult to follow, particularly for external stakeholders trying to understand where the company is gaining traction today.
Strong industrial biotech narratives usually balance two things carefully:
enough focus to make the immediate commercial pathway and beachhead market clear,
while still maintaining visibility of broader long-term platform potential and secondary application industries.
In practice, this may mean building a communication and content strategy that intentionally over-indexes on the primary commercial market while still maintaining a lighter but visible presence across secondary industries.
A website, for example, may balance platform technology and broader application potential while dedicating more extensive sections, proof points, and case studies to the company’s immediate commercial focus. Similarly, trade press activity, conferences, and industry events can be calibrated to favour the priority market without completely disappearing from exploratory application industries where early signals of future relevance still matter.
The challenge is therefore not choosing between focus and breadth, but understanding how to organise both coherently.
A pragmatic and focused marketing and communication strategy supports fundraising and commercial efforts
The industrial biotech companies that communicate most effectively are not necessarily the ones producing the most content or making the broadest claims. Excessive boldness can sometimes even backfire- as buyers favor transparency and claims that strike a balance between creating excitement and managing realistically expectations.
Balancing commercial priorities, investor expectations, and application-market realities into a marketing and communications plan that remains coherent over time sounds complicated, but can be addressed with a pragmatic strategy that aligns narrative and marketing efforts with investment and commercial objectives within a short and medium time horizon (e.g. 12 to 18-24 months).
In the context of industrial biotech, strong communication is not simply about visibility for the sake of visibility, which is helpful but rarely moves the needle in a meaningful way.
Marketing should be seen as an enabler of commercial efforts and fundraising.
For this reason, an effective communications strategy should involve CEOs, CBOs and head of sales.
Content plans should be created to enable the account-based marketing efforts of sales teams, so that warm leads can be re-engaged through relevant technical articles, industry coverage, rich content- press efforts should be aligned with the titles that offer more credibility and relevance for specific applicaton industries or for investors.
Trade events, congresses and shows where buyers and investors will be present and engaged face-to-face need to become cornerstones of the marketing calendar.
In an sector with long negotiations and multiple touchpoints, a solid marketing and communications plan ‘‘follows’’ the audiences and engages with them multiple times, across multiple channels- online, offline and in-person.
EDERA Lab is a marketing and communications partner for industrial biotech and industrial innovation companies, helping teams translate complex technologies into clear narratives for investors, buyers and partners. Explore our industrial biotech work with AmphiStar, or get in touch to discuss your positioning, PR and marketing needs.
